With multi-indication PBS listing widening immunotherapy access for advanced and metastatic cancers, ‘clinical judgement and discretion’ takes on new meaning for oncologists. Watch again as an expert panel discusses the implications for the health system and considers patient, clinical and medico-legal perspectives.

Click on chapters below to view topics

Chapter 1: Perspectives from the Chair of MOGA

Chapter 2: Perspectives from the Chair of PBAC

Chapter 3: Perspectives from the Deputy Chair of MOGA ethics committee

Chapter 4: Medicolegal perspectives

Developed in partnership with MOGA

Hosted by Associate Professor James Lynam
Chair, Medical Oncology Group of Australia (MOGA); Senior Clinical Advisor, Cancer Institute NSW.

PANEL

Professor Robyn Ward AM. Chair, Pharmaceutical Benefits Advisory Committee (PBAC); Deputy Vice-Chancellor (Research and Enterprise) and Senior Vice-President, Monash University.

Dr Owen Bradfield. Chief Medical Officer, Medical Indemnity Protection Society (MIPS); Health Law Researcher, University of Melbourne.

Dr Sarah Heynemann. Deputy Chair, MOGA ethics committee; Medical Oncologist, Melbourne; PhD candidate, Sydney Health Ethics, University of Sydney.

For more information, please contact [email protected]

Thank you to our partner

Sponsored by

This webinar was supported by unrestricted educational grants and created independently by the Medical Oncology Group of Australia (MOGA) in collaboration with the limbic. All content is selected by the participants and all views expressed are those of the participants only.